von Rosenstiel1 C, Wiestler B, Haller B, et al. - Researchers sought to assess the effect of MGMT promoter methylation in individuals with primary diagnosed glioblastoma (GBM) relating to survival applying a quantitative method (methylation quantification of endonuclease-resistant DNA, MethyQESD) by verifying a cut-off point for MGMT methylation provided by the literature and calculating an optimal cut-off. They retrospectively examined 67 individuals aged 70 years or younger, operated between January 2013 and December 2015, with newly diagnosed IDH wild-type GBM and clinical follow-up. In newly diagnosed individuals with GBM, they found that the quantitative level of MGMT promoter methylation is a positive prognostic factor. The data indicated that the cut-off is given by the literature ( Go to Original